← Back to Search

5-HT3 Receptor Antagonist

Palonosetron HCl Buccal Film 0.5 mg for Nausea and Vomiting

Phase 3
Waitlist Available
Research Sponsored by Xiamen LP Pharmaceutical Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 hours post chemotherapy, 24-120 hours post chemotherapy, and up to 120 hours post chemotherapy
Awards & highlights

Summary

This trial is testing a new way to give palonosetron, a drug that prevents nausea and vomiting from chemotherapy, using a dissolvable film in the mouth instead of an injection. It targets cancer patients who often feel sick from their treatment. The drug works by stopping the brain signals that make you feel nauseous and vomit.

Eligible Conditions
  • Nausea and Vomiting

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 hours post chemotherapy, 24-120 hours post chemotherapy, and up to 120 hours post chemotherapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 hours post chemotherapy, 24-120 hours post chemotherapy, and up to 120 hours post chemotherapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Absence of nausea
Complete control
Complete response
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Palonosetron HCl Buccal FilmExperimental Treatment1 Intervention
Palonosetron HCl Buccal Film 0.5 mg 1 hr before administration of moderately emetogenic chemotherapy and normal saline injection 30 minutes before administration of moderately emetogenic chemotherapy
Group II: Palonosetron IV InjectionActive Control1 Intervention
Placebo buccal film 1 har before administration of moderately emetogenic chemotherapy and Palonosetron HCl Injection 0.25 mg 30 min before administration of moderately emetogenic chemotherapy

Find a Location

Who is running the clinical trial?

Xiamen LP Pharmaceutical Co., LtdLead Sponsor
1 Previous Clinical Trials
22 Total Patients Enrolled

Media Library

Palonosetron (5-HT3 Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05199818 — Phase 3
Nausea and Vomiting Research Study Groups: Palonosetron HCl Buccal Film, Palonosetron IV Injection
Nausea and Vomiting Clinical Trial 2023: Palonosetron Highlights & Side Effects. Trial Name: NCT05199818 — Phase 3
Palonosetron (5-HT3 Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05199818 — Phase 3
~94 spots leftby Sep 2025